高渗盐水与羧甲司坦改善支气管扩张气道清除的2×2析因随机试验方案
CLEAR试验为52周、2×2析因、随机、开放标签研究,在成人支气管扩张患者中比较每日两次雾化6%高渗盐水、羧甲司坦或两者联合与常规护理的临床和成本效果。主要结局为52周内平均急性加重次数,受试者需CT确诊支气管扩张、以支气管扩张为主要呼吸诊断、过去一年至少两次需抗生素的急性加重且每日有痰。
要点
- 比较6%高渗盐水、羧甲司坦及联合方案与常规护理对支气管扩张急性加重的影响。
- 主要结局为52周内平均急性加重次数,同时评估成本效果。
- 纳入标准包括CT确诊、过去一年至少两次需抗生素的急性加重且每日有痰。
核心结论
- 该试验旨在明确高渗盐水、羧甲司坦或两者联合能否减少支气管扩张患者52周内的急性加重并具成本效果。
研究设计与样本
- 52周、2×2析因、随机、开放标签试验,比较6%高渗盐水、羧甲司坦、两者联合与常规护理。
关键数值与推荐
- 高渗盐水组:每日两次雾化6%高渗盐水。
- 羧甲司坦组:750 mg每日三次至第3次访视,后减为750 mg每日两次。
- 主要结局:52周内平均急性加重次数。
- 纳入标准:CT确诊支气管扩张、以支气管扩张为主要呼吸诊断、过去一年至少两次需抗生素的急性加重且每日有痰。
局限性
- 开放标签设计可能引入实施与结局评估偏倚,方案未报告盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a combination) are effective in reducing exacerbations over a 52-week period, compared to usual care. METHODS: This is a 52-week, 2 × 2 factorial, randomized, open-label trial to determine the clinical effectiveness and cost effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care - the Clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care (CLEAR) trial. Patients will be randomised to (1) standard care and twice-daily nebulised HTS (6%), (2) standard care and carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day), (3) standard care and combination of twice-daily nebulised HTS and carbocisteine, or (4) standard care. The primary outcome is the mean number of exacerbations over 52 weeks. Key inclusion criteria are as follows: adults with a diagnosis of BE on computed tomography, BE as the primary respiratory diagnosis, and two or more pulmonary exacerbations in the last year requiring antibiotics and production of daily sputum. DISCUSSION: This trial's pragmatic research design avoids the significant costs associated with double-blind trials whilst optimising rigour in other areas of trial delivery. The CLEAR trial will provide evidence as to whether HTS, carbocisteine or both are effective and cost effective for patients with BE. TRIAL REGISTRATION: EudraCT number: 2017-000664-14 (first entered in the database on 20 October 2017). ISRCTN.com, ISRCTN89040295. Registered on 6 July/2018. Funder: National Institute for Health Research, Health Technology Assessment Programme (15/100/01). SPONSOR: Belfast Health and Social Care Trust. Ethics Reference Number: 17/NE/0339. Protocol version: v3.0 Final_14052018.
引用
- Bradley JM, Anand R, O'Neill B, et al. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. Trials. 2019. PMID: 31856887. doi:10.1186/s13063-019-3766-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。